Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification

Si Chen, Thien Le, Brendan A.c. Harley, P. I. ImoukhuedeFrontiers in Bioengineering and Biotechnology 2018 · DOI

Abstract

Dysregulation of tyrosine kinase receptor (RTK) signaling pathways play important roles in glioblastoma (GBM). However, therapies targeting these signaling pathways have not been successful, partially because of drug resistance. Increasing evidence suggests that tumor heterogeneity, more specifically, GBM-associated stem and endothelial cell heterogeneity, may contribute to drug resistance. In this perspective article, we introduce a high-throughput, quantitative approach to profile plasma membrane RTKs on single cells. First, we review the roles of RTKs in cancer. Then, we discuss the sources of cell heterogeneity in GBM, providing context to the key cells directing resistance to drugs. Finally, we present our provisionally patented qFlow cytometry approach, and report results of a "proof of concept" patient-derived xenograft GBM study.

Introduction

Glioblastoma (GBM) is the most aggressive and lethal primary brain tumor in adults. While Receptor Tyrosine Kinase (RTK) signaling—which governs cell growth and angiogenesis—is known to be dysregulated in these tumors, clinical trials for drugs targeting these receptors (such as EGFR or VEGFR inhibitors) have largely failed.

The primary obstacle is tumor heterogeneity. A GBM tumor is not a uniform mass but a complex mosaic of distinct cell types, including glioblastoma stem cells (GSCs) and tumor-associated endothelial cells (ECs). Standard "ensemble" sequencing methods, which analyze bulk tumor samples, average out the signals from these rare but critical sub-populations. To develop effective therapies, it is essential to quantify the absolute number of receptors on the surface of specific cells, as these membrane-bound proteins serve as the primary docking stations for targeted drugs.

Methods: The qFlow Cytometry Approach

We introduce qFlow cytometry, a high-throughput method that provides absolute protein quantification rather than relative qualitative results.

Overview of the qFlow cytometry workflow, illustrating the process from the GBM PDX model to single-cell isolation, quantitative flow cytometry, and subsequent heterogeneity analysis.

The qFlow workflow utilizes fluorescent calibration beads with a known number of fluorophores to convert raw signal intensity into the absolute number of receptors per cell. In our proof-of-concept study using the GBM39 PDX model (characterized by the EGFRvIII mutation), we isolated cells into four categories: human tumor EC-like cells (hCD34+), mouse stromal EC-like cells (mCD34+), glioblastoma stem cells (hCD133+), and bulk tumor cells. We then employed Gaussian mixture modeling to identify sub-populations and Quadratic Entropy (QE) to calculate a diversity score for receptor expression.

Results and Discussion

Our analysis revealed several key insights into the molecular landscape of GBM:

  • The GSC "Invisibility Cloak": A critical finding was that GSCs—the cells responsible for tumor recurrence—exhibited approximately 13-fold lower surface expression of EGFR and IGFR compared to the bulk tumor. This suggests that drugs targeting these receptors may fail because the "roots" of the tumor lack the necessary targets.
  • Vascular Heterogeneity: Human tumor-associated EC-like cells showed significantly higher heterogeneity than healthy vessels. A small sub-population (8%) of these cells possessed 12 times the average amount of EGFR, potentially driving resistance in the tumor vasculature.
  • Species-Specific Stroma: Mouse-derived vessels within the human tumor graft maintained receptor ratios similar to healthy tissue, whereas human-derived EC-like cells were highly abnormal, emphasizing the need to distinguish between host response and hijacked tumor cells.
Detailed analysis of cell composition and RTK heterogeneity metrics (Quadratic Entropy vs. Mixture Components) used to evaluate the targetability of specific receptors.

In the GBM39 model, we identified VEGFR2 and PDGFRα as the most viable targets for disrupting tumor vessels, as over 70% of the target cells expressed these receptors at high levels with low heterogeneity (QE < 0.35).

Conclusion and Future Directions

This pilot study demonstrates that absolute quantification can identify druggable targets that are otherwise hidden by bulk analysis. While these "protein barcodes" likely vary between patients, the qFlow approach provides a framework for personalized medicine.

Future work will focus on:

  1. Multiplexing: Utilizing mass cytometry (CyTOF) to map 30+ receptors simultaneously.
  2. Clinical Baselines: Establishing a library of receptor concentrations in healthy brain tissue to define "druggable" thresholds.
  3. Predictive Modeling: Integrating absolute counts into computational models to predict optimal drug combinations for individual patients.

Summary updated

Abstract

Dysregulation of tyrosine kinase receptor (RTK) signaling pathways play important roles in glioblastoma (GBM). However, therapies targeting these signaling pathways have not been successful, partially because of drug resistance. Increasing evidence suggests that tumor heterogeneity, more specifically, GBM-associated stem and endothelial cell heterogeneity, may contribute to drug resistance. In this perspective article, we introduce a high-throughput, quantitative approach to profile plasma membrane RTKs on single cells. First, we review the roles of RTKs in cancer. Then, we discuss the sources of cell heterogeneity in GBM, providing context to the key cells directing resistance to drugs. Finally, we present our provisionally patented qFlow cytometry approach, and report results of a "proof of concept" patient-derived xenograft GBM study.
BibTeX
@inproceedings{chen2018characterizing,
  author = {Si Chen and Thien Le and Brendan A.C. Harley and P. I. Imoukhuede},
  title = {{Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification}},
  booktitle = {Frontiers in Bioengineering and Biotechnology},
  year = {2018},
  doi = {10.3389/fbioe.2018.00092},
}
Figure